an update on imetelstat in r/r myelofibrosis
Published 2 years ago • 674 plays • Length 1:44Download video MP4
Download video MP3
Similar videos
-
1:15
ongoing trials of ruxolitinib, momelotinib and imetelstat in myelofibrosis
-
1:44
imerge update: continuous transfusion independence & disease modification with imetelstat in lr-mds
-
1:25
the recent approval of imetelstat in lr-mds based on results of the imerge trial
-
6:50
an overview of the immunotherapy landscape in aml: antibodies, bispecifics, & car-t
-
4:39
imetelstat shows promise in advanced myelofibrosis
-
21:38
drawing the line: the rationale behind blood tube collection order
-
3:19
first-line treatment selection in myelofibrosis
-
1:28
momelotinib in 2024: how should this agent be used in mf with anemia?
-
1:52
an update on the use of navtemadlin in myelofibrosis
-
1:24
imetelstat in high-risk triple-negative myelofibrosis
-
1:40
the role of imetelstat in the treatment of myelofibrosis and insights into the impactmf study
-
1:30
the safety profile of imetelstat in myeloid malignancies
-
1:04
exciting updates in mf: novel targets and agents
-
3:35
new phase iii trial of imetelstat versus bat in jak inhibitor-refractory myelofibrosis
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
2:51
analysis of the imerge trial: the disease-modifying potential of imetelstat in lr-mds
-
3:12
prolonged & continuous transfusion independence after imetelstat treatment in the imerge trial
-
3:13
therapies for patients who progress on jak inhibitors: imetelstat, navtemadlin, selinexor & tp-3654
-
1:52
results of phase i study of mcl-1 inhibition with azd5991 in r/r hematologic malignancies
-
1:09
menin inhibitors for the treatment of aml: insights into the covalent-101 trial
-
2:57
imetelstat for lr-mds: insights from the imerge trial